{"id":"tq-b3139","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"TQ-B3139 inhibits receptor tyrosine kinases and intracellular signaling pathways critical for tumor growth. The drug is designed to block multiple oncogenic pathways simultaneously, potentially providing broader anti-tumor activity. It is being developed by Chia Tai Tianqing Pharmaceutical Group as an oral small-molecule therapeutic.","oneSentence":"TQ-B3139 is a tyrosine kinase inhibitor that targets multiple kinases involved in cancer cell proliferation and survival.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:39:35.268Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Solid tumors (specific indications under investigation in Phase 3)"}]},"trialDetails":[{"nctId":"NCT04675060","phase":"PHASE1","title":"Effect of High-fat Meal on the Pharmacokinetics of TQ-B3139 Capsules","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2021-02-23","conditions":"Advanced Solid Tumors","enrollment":12},{"nctId":"NCT04398940","phase":"PHASE2","title":"A Study of TQ-B3139 Capsules in Subjects With MET-Altered Advanced Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2020-08-11","conditions":"Non Small Cell Lung Cancer","enrollment":71},{"nctId":"NCT04056572","phase":"PHASE2","title":"Study of TQ-B3139 in Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2019-08-13","conditions":"ALK-positive NSCLC","enrollment":135},{"nctId":"NCT04009317","phase":"PHASE3","title":"Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2019-08-13","conditions":"ALK-positive NSCLC","enrollment":260},{"nctId":"NCT03099330","phase":"PHASE1","title":"A Phase I Study of TQ-B3139 on Tolerance and Pharmacokinetics","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2017-07-19","conditions":"Advanced Cancer","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"TQ-B3139","genericName":"TQ-B3139","companyName":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","companyId":"chia-tai-tianqing-pharmaceutical-group-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TQ-B3139 is a small molecule being studied as a potential treatment for various types of cancer, including non-small cell lung cancer and advanced solid tumors. It is being investigated in a clinical trial, NCT04398940, in combination with crizotinib for MET-altered advanced non-small cell lung cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}